USPA Global 与 ESPN 深化合作,携手克里斯·福勒共同呈现 2026 年高目标马球锦标赛 ACN Newswire

USPA Global 与 ESPN 深化合作,携手克里斯·福勒共同呈现 2026 年高目标马球锦标赛

佛罗里达州西棕榈滩, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - USPA Global旗下娱乐子公司Global Polo延续与ESPN的深厚合作关系,继续向全球数百万家庭推广马球运动。此次具有里程碑意义的合作包括:ESPN传奇解说员克里斯·福勒将首次主持3月29日的USPA金杯赛®决赛,并连续第二年主持4月26日的美国公开马球锦标赛®决赛。赛事将在佛罗里达州棕榈滩县的USPA国家马球中心举行,届时他将与资深播音员肯尼·赖斯以及马球名人堂成员亚当·斯诺共同主持。Legendary ESPN Commentator, Chris Fowler, at the USPA National Polo Center in Palm Beach County, FloridaPhoto Credit: Alex Pacheco“我有幸报道过体育界一些最具标志性的赛事,而让我不断回归马球运动的,是马球运动员与马球马之间独特的伙伴关系,以及最高水平比赛中展现的速度与激烈程度,”福勒表示。“主持USPA金杯赛和美国公开马球锦标赛,让我能够将这项美丽运动的活力与独特性分享给更广泛的ESPN观众。”“没有什么能比得上亲眼目睹这些世界级运动员与他们的马匹伙伴在这项节奏快、充满策略的比赛中竞技的体验,”福勒补充道。USPA金杯赛始于1974年,是美国马球界仅次于美国公开马球锦标赛(始于1904年)的第二大赛事。今年的赛事将于3月4日至29日举行,届时将有10支精英队伍在最高水平的竞技中一决高下。而备受瞩目的美国公开马球锦标赛将于4月1日至26日举行,该赛事被公认为众多世界顶级球员和马匹的展示舞台,至今仍是全球最负盛名的马球赛事之一。自2004年落户佛罗里达州棕榈滩县以来,这两项赛事便一直接连举行。这些备受瞩目的马球赛事将在佛罗里达州韦灵顿的美国马球协会(USPA)国家马球中心(NPC)内的美国马球协会体育场一号场举行。4月初的USPA金杯赛决赛以及5月的美国公开马球锦标赛决赛,都将在ESPN2等ESPN旗下多个平台进行转播。具体播出时间请查阅当地节目表。“我们与ESPN的长期合作关系持续推动着马球运动、U.S. Polo Assn.品牌及其背后的全球发展势头,”管理着价值数十亿美元的全球体育品牌U.S. Polo Assn.的公司——USPA Global总裁兼首席执行官J·迈克尔·普林斯表示。“克里斯·福勒的回归以及他将同时主持USPA金杯赛和美国公开马球锦标赛的扩展参与,进一步增强了这些世界级赛事在全球观众中的势头和知名度。”“在ESPN的支持下,马球运动持续吸引着全球粉丝的关注,”普林斯补充道。除赛事直播外,ESPN平台还将播出由Global Polo制作、两度获奖的节目《Breakaway:U.S. Polo Assn.呈现》的新一季内容。观众可通过Global Polo的YouTube频道观看独家幕后花絮、球员特写及锦标赛精彩集锦,其中包括与USPA金杯赛和美国公开马球锦标赛转播相关的特别报道。“美国马球协会(USPA)很高兴看到这项运动通过与ESPN的合作持续发展,”美国马球协会(USPA)主席斯图尔特·阿姆斯特朗表示。“USPA金杯赛和美国公开马球锦标赛代表了美国赛季中USPA国家马球中心最高水平的竞技,而ESPN带来的更高曝光度,彰显了定义我们这项运动的运动精神、奉献精神和传统。”如需获取最新资讯和突发新闻,请访问 globalpolo.com 订阅《马球内幕》通讯,并浏览 uspolo.org。关于ESPN作为全球领先的多平台体育娱乐品牌,ESPN旗下拥有七家美国电视网络、领先的体育应用程序、面向消费者的流媒体服务ESPN+、领先的社交及数字平台、ESPN.com、ESPN Audio,业务遍及全球各大洲,此外还有更多业务。关于 U.S. Polo Assn. 和 USPA GlobalU.S. Polo Assn. 是美国马球协会(USPA)的官方运动品牌。USPA 成立于 1890 年,是美国规模最大的马球俱乐部和马球运动员协会。凭借数十亿美元的全球业务规模,以及通过1,200多家U.S. Polo Assn.零售店和数千个其他销售网点实现的全球分销网络,U.S. Polo Assn.为全球190多个国家的男女及儿童提供服装、配饰和鞋履。该品牌赞助了全球各大马球赛事,包括每年在棕榈滩的NPC举行的美国公开马球锦标赛®——这是美国最顶级的马球锦标赛。通过与美国ESPN、欧洲TNT和Eurosport以及印度Star Sports达成的历史性合作,由U.S. Polo Assn.赞助的数项世界顶级马球锦标赛现已实现电视转播,使全球数百万体育迷首次得以欣赏这项激动人心的运动。据《License Global》报道,U.S. Polo Assn. 一直与 NFL、PGA 巡回赛和一级方程式赛车并列,被评为全球顶级体育授权商之一。此外,这一受运动启发的品牌因全球业务增长和体育内容而屡获国际奖项。凭借其作为全球品牌的巨大成功,U.S. Polo Assn. 不仅登上了《福布斯》、《财富》、《现代零售》和《GQ》等杂志,还出现在雅虎财经和彭博社等全球众多知名媒体上。如需了解更多信息,请访问 uspoloassnglobal.com 并关注 @uspoloassn。USPA Global是美国马球协会(USPA)的子公司,负责管理价值数十亿美元的运动品牌U.S. Polo Assn.。USPA Global还管理其子公司Global Polo,后者是全球马球运动内容的领导者。如需了解更多信息,请访问globalpolo.com或YouTube上的Global Polo频道。关于美国马球协会®(USPA)美国马球协会®的成立宗旨在于推广马球运动;协调其会员俱乐部及注册球员会员的活动;组织并监督马球锦标赛、竞赛及比赛;并为相关赛事提供规则、让分制度及比赛条款。其总体目标是提升该项运动水平,并保障人类及马匹参与者的安全与福祉。USPA成立于1890年,是北美地区规模最大的马球志愿体育组织。目前,USPA拥有超过200家会员俱乐部和5,000多名注册球员会员。该协会每年主办并监督由其会员俱乐部承办的约50场全国性赛事。如需了解更多信息,请访问uspolo.org。如需更多信息,请联系:香农·斯蒂尔森(Shannon Stilson)——体育营销与媒体副总裁 电话 +001.561.227.6994 - 电子邮件:sstilson@uspagl.com斯泰西·科瓦尔斯基(Stacey Kovalsky)——全球公关与传播副总裁 电话 +001.954.673.1331 - 电子邮件:skovalsky@uspagl.com克里斯汀·卡尔卡尼奥 - ESPN传播部高级公关专员 电话 +001.959.216.8036 - 电子邮件:christine.b.calcagno@espn.com来源:USPA Global Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Media Troopers Teams with Canadian Gaming Law Firm to Gear Up for Alberta iGaming Launch iGame

Media Troopers Teams with Canadian Gaming Law Firm to Gear Up for Alberta iGaming Launch

(AsiaGameHub) - Leading digital marketing and customer acquisition firm Media Troopers has revealed it’s preparing to enter Alberta’s soon-to-launch regulated iGaming market through a partnership with Alon Segev, Managing Partner, and Ron Segev, founder of Canadian gaming and betting legal practice Segev LLP. Alberta is set to be Canada’s second province to regulate commercial online gambling, after Ontario did so in 2022. Last May, the province approved the iGaming Alberta Bill, which established a framework for operators to enter the market and created a new iGaming regulatory body—the Alberta iGaming Corporation. As part of its strategic entry into this new sector, Media Troopers has teamed up with Segev, which will advise the company on regulatory strategy, compliance requirements, and market readiness as Alberta finalizes its operational and licensing framework. “Alberta represents one of the most exciting emerging regulated markets in North America,” said Shmulik Segal, CEO of Media Troopers. “Working with Ron Segev and the team at Segev LLP ensures that our expansion into the province will be aligned with the evolving regulatory framework and positioned for long-term success.” Similar to Ontario’s competitive landscape, Media Troopers is committed to supporting licensed operators in Alberta through localized marketing channels, affiliate partnerships, and compliance-focused customer acquisition strategies. “Canada’s iGaming market continues to evolve rapidly,” Segal added. “Our goal is to be fully prepared to support operators entering Alberta from day one.” This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
ENJOY’s Italian market access achieved as regulated expansion strategy progresses iGame

ENJOY’s Italian market access achieved as regulated expansion strategy progresses

(AsiaGameHub) - ENJOY, a leading iGaming content developer, has received official certification to supply its products in the Italian market, marking a major milestone in the company’s European expansion strategy. After securing approval from Italy’s regulatory authority, Agenzia delle Dogane e dei Monopoli (ADM), ENJOY is now authorized to offer its full portfolio of slot titles, live casino offerings and hybrid live experiences to licensed operators across one of Europe’s most established and competitive iGaming jurisdictions. This certification represents a critical step in ENJOY’s long-term growth plans, allowing the company to enter the Italian market through a series of upcoming partnerships with leading local operators. These integrations will introduce Italian players to ENJOY’s unique mix of engaging game mechanics and high-quality production. The provider’s portfolio includes a range of top-performing slot titles built around proven game mechanics such as Bison Strike and recent launches like Hotfire Diamonds XXL. It also features a growing suite of live game show experiences including Enchanted Forest and the upcoming Energy Roulette Hold & Win, produced at its state-of-the-art studio. Italy’s mature regulatory framework and highly competitive landscape make it a strategically important market for suppliers looking to build a strong European presence, aligning closely with ENJOY’s focus on regulated growth and sustainable market entry. Christos Zoulianitis, Chief Commercial Officer at ENJOY, stated: “Securing certification for the Italian market is a key milestone in ENJOY’s European expansion. Italy is one of the most established and competitive regulated markets, and gaining approval to supply our content here reflects both the quality of our portfolio and our commitment to meeting the highest regulatory standards. “This certification allows us to move forward with a number of exciting operator partnerships, ensuring our games are introduced to Italian players in a way that supports long-term growth and strong player engagement.” This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
Peter & Sons Expands into the German Market via Partnership with Staatliche Toto-Lotto GmbH Baden-Württemberg iGame

Peter & Sons Expands into the German Market via Partnership with Staatliche Toto-Lotto GmbH Baden-Württemberg

(AsiaGameHub) - Peter & Sons, an innovative iGaming studio based in Barcelona, has expanded its European presence by entering into a new partnership with erwin, the virtual slots platform of Staatliche Toto-Lotto GmbH Baden-Württemberg, a highly respected and established gaming operator in Germany. Established in 1948, Staatliche Toto-Lotto GmbH Baden-Württemberg has developed a solid reputation for reliability, trust, and innovation in Germany's regulated gaming industry. The company is a key player in the nation's lottery system and continues to broaden its digital entertainment portfolio through licensed online gaming products. Since 2023,Staatliche Toto-Lotto GmbH Baden-Württemberg has offered virtual slot games at www.lotto-bw.de/erwin, where a wide variety of entertaining and attractive slots are available and regularly updated. Additionally, Staatliche Toto-Lotto GmbH Baden-Württemberg seeks to provide gambling products that meet the changing demands of its customers. The organization places a strong emphasis on integrity and security, making adherence to youth and player protection regulations a primary concern. Known for its collection of art-focused games, unique characters, and captivating game environments, Peter & Sons has gained worldwide acclaim for advancing creative limits in slot development. This collaboration will enable German players to enjoy a handpicked assortment of the studio's top releases, furthering Peter & Sons' expansion in regulated European markets. Yann Bautista, Founder and Commercial Director at Peter & Sons, said: "We are thrilled to collaborate with Lotto Baden-Württemberg, an operator that has built substantial trust among German gaming enthusiasts. Germany is a significant regulated market for our company, and partnering with such a reputable organization enables us to present our games to a wide audience that values premium entertainment and unique design." Barbie Nerz, Head of Online Games at Staatliche Toto-Lotto GmbH Baden-Württemberg: "Peter & Sons has established a reputation for creating visually impressive and highly captivating games, and we are pleased to integrate their portfolio into our platform. Our objective is consistently to deliver varied, premium content to players, and this alliance marks further progress in enhancing the entertainment options we provide." This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
EGT Digital to Display Key Innovations at BiS SiGMA Americas 2026 iGame

EGT Digital to Display Key Innovations at BiS SiGMA Americas 2026

(AsiaGameHub) - EGT Digital is set to take part in BiS SiGMA Americas 2026, which will run 6–9 April in São Paulo, Brazil, where attendees can connect with the company's team at stand L146. Fresh off its recent appearance at SBC Summit Rio, the firm continues to deepen its engagement in the Brazilian market, bringing a curated showcase of high-performing content and cutting-edge technology solutions. One of the event's key highlights will be Panda Ventura, one of EGT Digital’s most well-received recent launches. Pairing a unique visual identity with smooth, intuitive gameplay, this title offers a well-balanced flow that builds excitement naturally and encourages longer play sessions. As the first entry in the new Ventura series, it lays the foundation for a character-driven lineup that will soon expand to include Tiger Ventura. Alongside this title, attendees will get to explore a full portfolio of 180+ in-house slot titles, including the proven jackpot series Bell Link, Clover Chance, and Gods & Kings Link, all engineered to drive strong user engagement and consistent performance across global markets. EGT Digital will also present X-Nave, its modular iGaming platform that integrates Casino, Sportsbook, CRM, Payment Gateway, Bonus Hub, and a powerful Aggregator with 20,000+ games from 200+ providers. The platform features a high-performance Sportsbook that delivers flexible integration, advanced personalization, and a fast, seamless betting experience, while the company's proprietary AI boosts engagement through intelligent promotional tools and automated functionalities. Its participation in BiS SiGMA Americas underscores EGT Digital’s ongoing commitment to LATAM and Brazil, where it supports operators with scalable, high-performance solutions customized to meet local market needs. Attendees visiting booth L146 will also have the chance to view and test EGT’s VLT products, which were developed specifically for the Brazilian market. Following their successful debut at SBC Summit Rio earlier in March, the Video Lottery Terminals Super Sorte 27/27 ST and Super Sorte 43V, along with the online betting terminals Top Estrela and Bar Estrela, are expected to draw significant interest at SiGMA Americas. These terminals stand out for their modern design, user-friendly features, and engaging gaming experience. In addition, the popular multigame package GOLD VLT will also unveil its collection of 50 captivating titles, created for the local gaming audiences. With an expanding portfolio and a technology ecosystem built for performance and adaptability, EGT Digital continues to deliver solutions truly Designed to Perform. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
The Official Megaways Casino is Back — ‘Play the Mega Way’ iGame

The Official Megaways Casino is Back — ‘Play the Mega Way’

(AsiaGameHub) - SkillOnNet has brought back the official Megaways Casino by relaunching MegawaysCasino.com. The platform re-establishes itself as the ultimate destination for the Megaways mechanic, featuring a new design, updated branding, and a commitment to its core message: 'Play the Mega Way.' Since its 2016 debut, Megaways transformed the online gaming landscape. The dedicated casino now returns as a dynamic, entertainment-focused platform tailored for today's players. The casino debuts with an extensive collection of Megaways games, featuring titles such as Monopoly Megaways, Rasputin Megaways, Extra Chilli Megaways, and Bonanza—the pioneering game that first showcased the Megaways concept. Beyond its comprehensive Megaways selection, the site offers more than 8,000 games spanning premium slots, crash games, table games, and live casino options, providing extensive variety. Created by Big Time Gaming, Megaways revolutionized slot design through its dynamic reel-modifier system that provides up to 117,649 winning combinations per spin. This breakthrough fundamentally altered the online gaming industry's trajectory and emerged as one of the most iconic and broadly licensed mechanics in contemporary iGaming. Megaways Casino now stands as the sole official online casino brand completely committed to honoring this heritage. As part of SkillOnNet's portfolio, the brand makes its comeback with a contemporary, performance-driven platform, proprietary content, striking visual branding, and a sustained focus on the UK market. Giordana Anticoli Kalifa, Country Manager Emerging Markets at SkillOnNet, commented: "Play the Mega Way" represents more than just a slogan. It embodies the essence of Megaways—the intense pace, exciting diversity, and inherent unpredictability of the mechanic—and infuses it throughout the entire brand experience.Megaways has consistently ranked among the most influential and recognizable mechanics in online gaming. Through this relaunch, we're not merely reviving a brand; we're constructing a complete entertainment ecosystem centered around it. "'Play the Mega Way' captures our goal of converting the dynamic energy, massive scale, and unpredictable essence of the Megaways mechanic into a comprehensive brand experience. We cater to players who demand more." This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement ACN Newswire

SinoMab (03681.HK) Achieves Approximately 43.3% Year-over-Year Decrease in Annual Losses for 2025, Marking Significant Progress in Pipeline Advancement

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).During the year, loss for the year was approximately RMB105.0 million, decreased by RMB80.1 million from RMB185.1 million for the year ended 31 December 2024. The Company focused on SM17 Phase 1b clinical, transformation bridging study and preparation of Phase 2 clinical trial in 2025, of which the cost was less than large scale clinical studies in 2024. As at 31 December 2025, total funding available to use was approximately RMB351.5 million, representing a significant increase compared to RMB141.4 million as at 31 December 2024. During the year, the Group gained support from well-known institutional investors including Foresight, Fullgoal, and E Fund, completed two rounds of new share subscriptions under general mandate and successfully raised an aggregate amount of approximately HK$493.7 million in net proceeds. This drove net cash flows from financing activities for the Reporting Period to approximately RMB329.4 million, providing sufficient funding to support subsequent R&D and clinical advancement.SM17 Achieves Multiple BreakthroughsSM17 is a global first-in-class humanised monoclonal antibody (mAb) targeting the receptor for IL-25, which is capable of modulating Type II allergic reaction by targeting the receptor of a critical “alarmin” molecule interleukin-25 (IL-25). The compound has the potential for treating atopic dermatitis (AD), Inflammatory Bowel Disease (IBD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF).In the field of atopic dermatitis (AD), SM17 precisely targets upstream drivers of Type 2 immune responses by blocking IL-25, a key “alarmin” cytokine, thereby suppressing the inflammatory cascade at its source. While currently approved AD therapies, including biologics, can significantly improve Eczema Area and Severity Index (EASI) scores and patients’ quality of life, current drugs under development or on the market cannot simultaneously meet the clinical needs for rapid itch relief, skin lesion recovery, and good safety profiles, indicating substantial unmet market demand. SM17’s key innovation lies in its upstream modulation of the Th2 inflammatory cytokine pathway via IL-25 receptor inhibition, thereby suppressing multiple downstream pathogenic signaling pathways. Preclinical studies have demonstrated its potential for rapid itch relief, significant skin lesion recovery, and a favorable safety profile, directly addressing the key limitations of current therapies.In April 2025, SM17 achieved encouraging positive results in a Phase 1b study in China for the treatment of moderate to severe atopic dermatitis (AD): 12-week topline data after unblinding showed that in the high dose group, 91.7% of patients achieved pruritus relief (NRS-4), 75% achieved skin healing (EASI 75), and 41.7% achieved clear or almost clear signs of AD (IGA0/1). These results significantly outperform IL-4/IL-13 monoclonal antibodies and demonstrate a significantly better safety and tolerability profile than Janus Kinase inhibitors (JAK inhibitors), making SM17 potentially the first-in-class and best-in-class therapeutics which can simultaneously achieve rapid onset of action on pruritic relief, skin healing with a good safety profile. Study results of SM17 were published in various leading international journals. Phase 2 clinical trial for AD is expected to be entered into as early as mid-2026.On 11 December 2025, an Investigational New Drug application (“IND”) for SM17 in the indication of IBD was filed with and accepted by the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration of China (“NMPA”), and the IND was subsequently approved in February 2026. This IND submission represents an important step toward expanding SM17’s therapeutic scope beyond AD to IBD, including Crohn’s disease (“CD”) and ulcerative colitis (“UC”), which are chronic, debilitating conditions with significant unmet medical needs. In October 2025, the first cohort of healthy subjects was dosed in a Phase 1 bridging clinical trial for the route of administration conversion in China. As of 31 December 2025, a total of 30 healthy subjects had been enrolled and our follow-up visits for all healthy subjects were completed in February 2026. This bridging study is expected to be completed by the second quarter of 2026. Data from this study will be leveraged to support the progression of the IBD indication directly to Phase 2 clinical development.Early-Stage Pipelines Drive Continuous Innovation GrowthIn terms of early-stage pipeline development, the Company continues to make steady progress. In June 2025, Its partner, Everest Medicines, has announced positive results from the Phase Ib/IIa clinical trial of EVER001 (SinoMab’s SN1011) for the treatment of primary membranous nephropathy (PMN), further enhancing the commercial value of the pipeline.At the same time, multiple early-stage R&D programs are progressing steadily. Anti-CGC antibody is an in-house developed, first-in-class humanised anti-γc antibody. Our in vitro assays suggested that our antibody could suppress inflammation and autoimmunity driven B, T and NK cell activation. Animal studies demonstrated that our antibody could be a potential therapeutic agent for the treatment of vitiligo, alopecia areata and possibly other autoimmune diseases through the modulation of immune cell expansion, autoreactivity and tissue infiltration. We are currently in the process of CMC optimisation and toxicology studies for our antibody and plan to submit our IND application for the treatment of alopecia areata by the fourth quarter of 2026 at the earliest.Bispecific antibody candidate is a novel, bispecific antibody targeting Receptor activator of the nuclear factor kappa-B ligand (RANKL) and sclerostin for bone-related indications. bsAb processes differential mechanisms of action tailored for the treatment of osteoporosis. Our in-house in vitro and in vivo studies demonstrated our candidate to have enhanced efficacy over market-approved antibodies such as Denosumab and Romosozumab. We are currently in the process of optimising CMC and testing toxicity in non-human primates and plan to submit our IND application by the first half of 2027 at the earliest.Expanding Strategic Partnerships and Gaining Strong Industry RecognitionsIn August 2025, the Company entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Institute of Advanced Studies Hong Kong Limited (“SYSU-IAS”). Under the cooperation agreement, the Company enjoys direct access to SYSU-IAS’s comprehensive laboratory facilities and valuable data resources, as well as access to primate and non-primate animal studies supply resources, to accelerate the development of innovative drugs and promote the translation of scientific research into clinical applications worldwide. Furthermore, the Company is actively exploring the feasibility of using artificial intelligence (AI) technology for new target identification.In January 2026, the Company was invited to participate in the J.P. Morgan Healthcare Conference, where it shared its progress in the autoimmune field with multiple multinational pharmaceutical companies (MNCs) and investors.With the support of our strong R&D capabilities, extensive pipeline assets and refined operational management, we are thrilled to obtain renowned awards during the year, including the 2nd “New Quality Productive Forces Enterprise Award” jointly presented by the Greater Bay Area Family Office Association and the Hong Kong International Family Office Association, as well as the “Most Valuable Pharmaceutical Company Award” presented by Zhitong Finance.Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, comments: "In 2025, we demonstrated the global competitiveness of our innovative pipeline with solid clinical data. The outstanding performance of SM17 in AD and its indication expansion to IBD signify our continuous transition from single-product R&D to the realisation of platform value. Looking ahead to 2026, the biopharmaceutical industry has been accelerating into the “Biotech 3.0 Era”, which is characterised by innovation-driven development, multidisciplinary integration, and intelligent processes across the entire supply chain. We are well-positioned to capture the historic opportunity of the rapid growth of out-licensing deals in China’s biopharmaceutical industry, continue to advance the clinical development of our core pipelines, and deepen our international partnership footprint. Relying on our solid cash reserves, full-spectrum capabilities across the industry chain and the principle of differentiated innovation, we strive to maximize the returns of shareholders in the long run and provide life-changing breakthrough therapies for patients.”About SinoMab BioScience LimitedSinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies. This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.Investor and Media InquiriesContact Person: Bunny LeeCitrus JiangWendy HuangPhone: (852) 5316 9995Email: ir_sinomab@zhenzhuoglobal.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
中国抗体(03681.HK)2025年度亏损同比下降约43.3% 管线开发取得重大进展 ACN Newswire

中国抗体(03681.HK)2025年度亏损同比下降约43.3% 管线开发取得重大进展

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 中国抗体制药有限公司("中国抗体"或"公司",连同旗下附属公司统称"集团",股份代号:03681.HK)欣然公布截至2025年12月31日止年度("年内")的全年业绩。年内,公司亏损由截至2024年12月31日止年度的人民币1.85亿元减少人民币0.80亿元至约人民币1.05亿元,主要得益于公司聚焦SM17 1b期临床、剂型桥接研究及2期临床筹备,研发成本较2024年大规模临床研究有所下降。截至2025年12月31日,公司可动用资金总额约人民币3.52亿元,较上年同期的人民币1.41亿元显著增长。年内,集团获得睿远、富国、易方达等多家知名机构投资者支持,公司完成两轮股份配售,合计募集所得款项净额约4.93亿港元,带动融资活动所得现金流净额达人民币3.29亿元,为后续研发及临床推进提供了充足资金支持。核心产品SM17取得多项突破性进展SM17是全球首创(First-in-Class)的靶向IL-25受体的人源化单抗,通过靶向II型免疫核心"警戒素(Alarmin)"分子白细胞介素25(IL-25)受体,调节II型炎症反应。SM17具有治疗特应性皮炎(AD)、炎症性肠病(IBD)、哮喘、慢性鼻窦炎伴鼻息肉(CRSwNP)及特发性肺纤维化(IPF)的潜力。在特应性皮炎(AD)领域,SM17精准作用于II型免疫反应的上游,通过阻断被称作"警报素"的关键细胞因子IL-25,从源头上抑制导致AD的炎症级联反应。当前,已获批上市的AD疗法(包括生物制剂)虽然可以大大改善患者的湿疹面积和严重程度指数以及生活质量。然而目前在研在售药物无法同时满足快速起效止痒,皮损恢复,同时具备良好安全性的临床需求,市场尚存在巨大空间。SM17的创新之处在于,它通过靶向Th2炎性细胞因子通路上游(如IL-25受体),从而对下游信号通路的致病因子产生抑制效果,且在临床前研究中展现出快速止痒、显著修复皮损以及良好安全性的潜力,直击现有疗法痛点。2025年4月,SM17在中国治疗中重度特应性皮炎的1b期研究中,取得了令人鼓舞的积极结果:揭盲后的12周顶线数据显示,高剂量组的91.7%的患者实现瘙痒缓解指标(NRS-4),75%达到皮损恢复(EASI75)指标,41.7%达到完全或近乎完全清除AD症状指标(IGA 0/1)。该结果显著优于IL4/IL-13类单抗药物且安全性与耐受性显著优于Janus激酶抑制剂(JAK抑制剂),这使得SM17有望成为一款可同时实现快速止痒、皮肤损伤修复,且安全性表现优异的同类首创及同类最优疗法。SM17的研究成果已在多家国际顶级期刊发表。预计最早在2026年年中进入AD的2期临床试验。此外,SM17持续拓展出多个新的适应症,于本年度第二季度,SM17的适应症拓展进一步取得突破性进展。2025年12月11日,SM17用于治疗IBD的新药研究申请("IND")已提交予中国国家药品监督管理局("中国国家药监局")药品审评中心("药品审评中心"),并已获受理,且IND随后于2026年2月获批。此次IND的提交,代表着SM17治疗范围从AD拓展至IBD的重要里程碑,涵盖克罗恩病("CD")及溃疡性结肠炎("UC")等慢性、衰竭性疾病,这些疾病存在显著未满足的医疗需求。于2025年10月,首组健康受试者已在中国给药途径转换之1期桥接临床研究中给药。截至2025年12月31日,合共三十名健康受试者已入组且对全部健康受试者之随访于2026年2月完成。该桥接研究预期于2026年第二季度前完成。该研究数据将用作支持IBD适应症的进展直接推进2期临床开发。早期在研管线布局提供持续创新动力在早期在研管线方面,公司持续取得积极进展。2025年6月合作伙伴云顶新耀公布了EVER001(中国抗体SN1011)用于治疗原发性膜性肾病(PMN)的1b/2a期临床试验的积极结果,进一步提升了管线的商业化价值。同时,公司多项早期研发项目稳步推进。其中,抗CGC抗体是一款内部开发的全球首创人源化抗γc抗体。动物研究显示,该抗体可能透过调节免疫细胞的扩增、自身反应性及组织浸润,成为治疗白癜风、斑秃,甚至其他自身免疫性疾病的潜在治疗药物。目前正在针对该抗体进行CMC优化及毒理学研究,并计划最早在2026年第四季度前提交其治疗斑秃的IND申请。双特异性抗体候选药物是一种新型双特异性抗体,靶向核因子kappa-B配体受体激活因子(RANKL)及骨硬化蛋白,治疗骨相关适应症。通过的内部体外及体内研究显示,相较于市售批准的抗体(如地诺单抗及罗莫珠单抗),该候选药物展现出更佳的疗效。目前正在进行CMC优化,并在非人灵长类动物中测试其毒性,并计划最早在2027年上半年前提交IND申请。协同推进战略合作与BD授权,荣获多项重磅荣誉公司于2025年8月与中山大学香港高等研究院有限公司("SYSU-IAS")签订全面战略合作协议,本公司可直接使用SYSUIAS完备的实验室设施与宝贵的数据资源,并获得包括灵长类及非灵长类实验动物在内的科研资源支持,加速创新药物研发进程,推动科研成果在全球范围内向临床应用转化。同时公司正积极探索运用人工智能(AI)技术开展新靶点发现的可行性。2026年1月,公司受邀参加摩根大通医疗健康大会(JPM大会)并与多家MNC、投资者分享了公司在自免领域的进展。依托雄厚的研发实力、丰富的管线储备及精细化运营管理,公司于本年度荣获多项重磅荣誉,包括粤港澳大湾区家族办公室协会与香港国际家族办公室协会联合颁发的第二届"新质生产力企业大奖",以及智通财经授予的"最具价值医药公司奖"。中国抗体董事长、执行董事兼首席执行官梁瑞安博士表示:"2025年,我们凭借扎实的临床数据证明了创新管线的全球竞争力,SM17在AD中的优异表现及其向IBD的拓展,标志着我们正从单一产品研发迈向平台价值的持续兑现。展望2026年,生物医药行业正加速迈入‘生物技术3.0时代’,创新驱动、多学科融合及全产业链智能化将成为核心发展方向。我们将把握中国生物医药对外授权高速增长的历史机遇,持续推进核心管线的临床开发,深化国际合作布局。依托坚实的现金储备、完善的产业链能力以及差异化创新优势,为股东创造长期价值,并为患者提供具有突破性的治疗方案。"关于中国抗体制药有限公司中国抗体制药有限公司(股份代号:03681.HK)是首创新药及潜在同类最佳抗体药物研发领域的开拓者,专注于自身免疫性疾病、以及由此导致的神经系统疾病及其他难治的耗损性疾病,致力于解决未被满足的医疗需求。中国抗体始终致力于开发针对全新靶点及通过创新机制的治疗性抗体,旨在现有疗法效果不佳的领域实现差异化临床成果。其丰富的研发管线包括:SM17在AD治疗中展现出卓越的止痒效果、皮肤清除率及安全性,同时在哮喘和特发性肺纤维化(IPF)领域具有应用潜力;其旗舰抗CD22舒西利单抗,除了临床验证对类风湿关节炎(RA)具有临床疗效外,目前正针对系统性红斑狼疮(SLE)和阿尔茨海默病开展临床评估;另一款抗CGC(共同γ链)创新单抗,正准备进入治疗斑秃和白癜风的临床研究;中国抗体亦研发了一款能同时刺激骨骼生长及抑制骨骼流失、治疗骨质疏松症的双特异性抗体。中国抗体以突破性疗效为核心追求,不断重新定义患者护理标准,稳居突破性疗法领域的领军地位。此新闻稿由真灼财经代中国抗体制药有限公司发布投资者及媒体查询联络人:Bunny LeeCitrus JiangWendy Huang电话:(852)5316 9995电邮:ir_sinomab@zhenzhuoglobal.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Viral Claim Ties Epstein to 2008 Powerball Jackpot iGame

Viral Claim Ties Epstein to 2008 Powerball Jackpot

(AsiaGameHub) - In July of last year, a former Atlantic City Trump Plaza Hotel and Casino manager stated he had witnessed President Donald Trump and Jeffrey Epstein together at the casino property, accompanied by underage girls. Epstein's ties to the gambling industry seemingly extended even deeper. The troubling Epstein Files uncovered an email from an investigative journalist to withdrawn recipients, which provided information on how the controversial financier and convicted sex offender allegedly won a Powerball jackpot. Currently, a contentious post on X, which has amassed millions of views, claims that on July 2, 2008, Epstein won an $85 million Powerball jackpot. Controversy Over the Zorro Trust Name The winning Powerball numbers for that drawing were 4, 33, 46, 48, 52, with 17 as the red Powerball, with an $85 million jackpot. The ticket was purchased in Oklahoma and featured a one-time cash option of $41.3 million. The assertion from the X account that revived the lottery win speculation about the controversial, deceased criminal was examined by Grok, the artificial intelligence assistant developed by xAI, to assess the claims. Grok ultimately verified that the Zorro Trust had collected the $85 million jackpot as a lump-sum payment of approximately $29.3 million after taxes from the July 2, 2008 drawing, for a ticket bought in Altus, Oklahoma. According to Grok, the trust's name corresponds to Epstein's trust associated with his Zorro Ranch in New Mexico. Grok added that based on the Epstein files released by the Department of Justice, the "Zorro Trust (belonging to Epstein)" had won the jackpot. The AI assistant also confirmed that lottery officials at that time adhered to standard protocol, permitting anonymity via trust formation. Additionally, the social media platform's AI assistant noted that no fraud was substantiated. "The Name Was Simply a Coincidence" Brice Gordon, Epstein's ranch manager, was reportedly the trustee of the trust and the individual who signed the documents required to claim the prize, though this assertion has not been officially verified. More controversially, when the AI assistant was asked a separate question about how many times Epstein had won the lottery, it provided a contradictory response, stating that Epstein had never won the lottery. Although the 2008 Oklahoma Powerball jackpot was claimed by a Zorro Trust to maintain anonymity, local news reports from that period indicated the winner was a grocery store worker from Altus. The winner had apparently given her trust the same name as Epstein's Zorro entity for his New Mexico ranch. "The identical name was purely coincidental. References in recent files are unverified notes, not evidence. There are no recorded wins." Epstein's Zorro Ranch in Stanley was situated over 400 miles from Altus. New Mexico has participated in Powerball since 1996. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
HIES introduces plant-based lubricant that reduces air compressor lifecycle CO(2) emissions by 40% JCN Newswire

HIES introduces plant-based lubricant that reduces air compressor lifecycle CO(2) emissions by 40%

TOKYO, Mar 24, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi Industrial Equipment Systems Co., Ltd. (hereinafter HIES, part of Hitachi, Ltd. Connective Industries (CI) Sector) has launched “GREEN SCREW OIL”, a plantbased lubricant for oil-flooded screw air compressors. Because the plant-derived raw materials absorb CO₂ during growth, the new lubricant cuts manufacturing-stage CO₂ emissions by approximately 90%. Even including emissions at disposal, its CO2 emissions across the entire lifecycle can be reduced by approximately 40%(estimated value) compared to conventional synthetic oils.Air compressors are widely used manufacturing and social infrastructure fields. HIES' air compressors form a significant part of the installed base for “HMAXTM(*1) Industry”, a digital service that embodies Lumada 3.0(*2), offering predictive diagnostics powered by machine learning and operational/maintenance support through generative AI. Delivered via “FitLiveTM(*3)”. These solutions support efficient and sustainable operations. Aligned with Hitachi’s sustainability strategy “PLEDGES(*4)”, which is based on the management plan “Inspire 2027,” and promotes decarbonization under the P: Planet pledge, “GREEN SCREW OIL” further enhances the environmental value of digitalized assets and supports the creation of more sustainable industrial sites.Product OverviewOil-flooded screw air compressors require lubricants to prevent component wear and provide cooling, as a pair of screw rotors rotate at high speeds to compress air. Conventional lubricants are derived from crude oil, and CO2 is emitted during their manufacturing process. “GREEN SCREW OIL” uses plants as raw materials that absorb CO2 through photosynthesis. This means that during manufacturing, CO2 emissions are reduced by 90%. Even when considering the disposal stage, total emissions are reduced by 40%. Its performance is equivalent to conventional synthetic oils, and it can be used with a two-year replacement cycle.Going forward, we also plan to expand this initiative to Hitachi Global Air Power's oil-flooded screw air compressors, which are under Sullair brand within Hitachi Group, and HIES’ oil-free air compressors. Hitachi Group air compressors hold a significant global market share. We estimate that replacing all lubricant used in the Group's air compressors with plant-based alternatives could reduce CO2 emissions by over 2,000 tons annually.Hitachi’s Connective Industries (CI) Sector, to which HIES belongs, focuses on “Integrated Industry Automation”, which aims to expand “HMAX Industry” into growth industries horizontally. HMAX Industry provides next-generation solutions for the industrial field that combines data from an abundant installed base of products (digitalized assets), domain knowledge, and advanced AI. As part of the CI Sector, HIES aims to drive innovation for frontline workers through the delivery of “HMAX Industry” that embodies Lumada 3.0.(*1) Hitachi Group's next-generation solutions leveraging AI to innovate social infrastructure, deployed globally and across industries(*2) Lumada 3.0: An evolution of Lumada, leveraging AI enhanced with Hitachi's domain knowledge. Lumada is the collective term for Hitachi's advanced digital technologies—solutions, services, and technologies—designed to extract value from customer data and accelerate digital innovation.(*3) FitLive® Introduction Page (Hitachi Industrial Equipment Corporate Site, Japanese only)(*4) Hitachi Ltd. press release (June 27, 2025) “Hitachi's new sustainability strategy "PLEDGES"”About HIESHIES enhances productivity across various industries — including data centers, batteries, electronics and semiconductors and pharmaceuticals — through high-efficiency products such as compressed air systems, grid edge solutions, drives and coding and marking equipment. Our innovative solutions and services integrate digital technology to drive customer success and contribute to a more sustainable society. We support customers throughout the entire product lifecycle, from maintenance to recycling. For more information on Hitachi Industrial Equipment Systems, please visit https://www.hitachi-ies.com/Business ContactHitachi Industrial Equipment SystemsGlobal Air Power Group Marketing & SalesManagement DivisionMarketing & Strategic Planning Dept.HIES-MSM-marketing@hitachi-ies.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
连接世界,驱动卓越增长:Apexmind Summit 2026在香港成功举办 Finance

连接世界,驱动卓越增长:Apexmind Summit 2026在香港成功举办

(SeaPRwire) - 香港,2026年3月24日——2026年Apexmind峰会今日在香港盛大举行。峰会汇聚了全球顶尖战略家、学者、商业与政策领袖,围绕战略机遇如何重塑竞争格局展开高层对话。活动期间,Apexmind Consulting香港办公室启用仪式正式宣布,Apexmind Consulting创始人兼董事长姚荣军先生获颁香港管理顾问协会(IMCHK)荣誉会士。这两大里程碑标志着以Apexmind为代表的中国战略咨询力量正通过香港积极与全球商业实现“文化握手”,在“战略共进化”愿景下,以有意义、可落地的方式推进全球拓展。 重新定义竞争逻辑,诠释新时代战略本质 Apexmind Consulting创始人兼董事长姚先生发表主旨演讲,深刻剖析了新时代竞争动态的演变。他强调:“竞争不是满足需求,而是赢得心智;企业的目的不是创造顾客,而是占据心智中的位置;企业经营不是提升效率,而是赢得人心;决策不应从内向外做,而应从外向内做;战略不是局部的总和,而是一个完整的系统。”在他看来,随着中国企业从产品全球化向品牌与模式全球化跃迁,全球市场迫切需要一种既具备普适性、又能与世界对话的战略语言。 获国际专业力量认可,共建全球咨询新生态 国际管理咨询协会理事会主席Nicholas Warn发表主旨演讲,表达了与Apexmind深度合作、共同构建全球商业生态、推动行业进化的愿景。他表示:“中国咨询机构,尤其是像Apexmind这样的机构,能够为我们带来的是对现有内容的丰富。”这一来自全球权威咨询组织的认可,叠加姚先生同日获颁IMCHK荣誉会士,标志着中国战略咨询正从全球商业智慧的接收者,向原创战略思想体系的共创者发生关键转变。 锁定七大战略机遇,绘制中国企业增长蓝图 Apexmind Consulting联席总裁陈吉先生现场发布《中国企业七大战略机遇》,提出结构化战略方法论,为企业提供清晰可落地的增长路径与突破方向。每一项机遇均沉淀自62家企业的实战战略 engagements(注:此处保留原文术语),这些框架能帮助企业将外部不确定性转化为可持续增长的确定性。 从香港到世界:赋能大湾区共成长 来自学界、行业协会与商界的嘉宾进一步分享洞见。香港中文大学石维磊教授从全球视角提出,中国企业的跨国战略必须锚定本土化与全球协作之间的平衡核心。香港科技大学教授、香港科技大学上海中心主任杨扬先生以智慧城市中的颠覆性创新场景为例,指出AI时代的数据与算法正为全球创业者打开全新竞争赛道。 香港管理顾问协会(IMCHK)会长Daniel Chan表示,香港正从“超级联系人”升级为“超级价值链增强者”,通过双向赋能为中国企业出海与国际企业入华搭建战略桥梁,彰显其枢纽独特价值。香港中华厂商联合会副会长黄伟鸿博士从香港视角出发,解读品牌如何依托区域优势与战略智慧,在新消费浪潮中实现战略突破路径。 Apexmind Consulting香港办公室的设立与本次峰会的圆满落幕,是Apexmind全球征程的一小步,却是中国战略咨询迈向“文化握手、战略共进化”的一大步。凭借助力62家企业实现十亿级规模化增长的实战积淀,Apexmind Consulting正从树立本土标杆迈向贡献全球标准,持续推动行业向前。未来,Apexmind将秉持开放视野,把根植中国、实战验证的战略框架带向国际舞台。在全球商业格局的演变中,Apexmind Consulting正引领中国咨询业向全球新高度跃升。 CONTACT: 曹阳 cy@qiaodong.net 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Secret Spending and Trading Card Mania Burden Couples’ Finances iGame

Secret Spending and Trading Card Mania Burden Couples’ Finances

(AsiaGameHub) - Infidelity in a relationship is typically a straightforward concept. But infidelity can manifest in other ways, and one key form revolves around financial matters. This is what’s now referred to as financial infidelity—a major source of relationship strain that’s growing increasingly prevalent. Dishonesty About Money Though less dramatic than traditional infidelity, financial infidelity shows up in similar ways: hiding expenses, keeping separate bank accounts secret, and minimizing debts. Over time, these behaviors can escalate into larger problems. A study by the National Endowment for Financial Education finds that a significant number of partnered adults have lied about money at some point. Even more report that financial secrecy has affected their relationship—particularly trust, which is far harder to restore than a depleted bank account. It’s Easier to Spend and Invest A key driver of financial infidelity is how easy it now is to spend or invest money without others finding out—thanks to mobile apps, online marketplaces, and digital wallets. For some, this leads to habits that look like risky behavior, especially when funds are tied to speculation. One area gaining increasing attention is the expanding trading card market—a once-nostalgic childhood hobby that’s now a thriving industry. Enthusiasts keep collecting rare cards that fetch high prices, fueling tales of big profits and adding allure through a blend of nostalgia and the dream of quick cash. But the very aspects that make trading cards exciting also make them unstable—prices hinge on trends, popularity, or the fame of the athletes featured on the cards. Experts note that this kind of market can act like gambling—with uncertain outcomes and a powerful urge to keep spending. Financial secrecy often takes root in such environments. Someone might start with small buys and slowly ramp up spending, especially if they think a big payout is imminent. Rather than discussing worries, they might hide losses or put off tough talks. Outside Help May Be Needed Couples who openly and honestly discuss income, debt, and goals tend to be better prepared to handle various challenges. Setting a joint budget and agreeing on limits for non-essential spending is a great way to sharply reduce conflict risk. For more serious issues involving significant sums, outside help from financial advisors and counselors can have a major impact. Ultimately, financial stability isn’t just about how much money comes in or goes out—it’s also about transparency, communication, and making decisions together. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
同仁堂医养(02667.HK)基石锁定逾46% “百年中医第一股”认购进入最后倒计时 ACN Newswire

同仁堂医养(02667.HK)基石锁定逾46% “百年中医第一股”认购进入最后倒计时

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 这家承载356年品牌传承的中医医疗服务龙头近日正在港股招股,背靠"老字号",补齐了同仁堂集团"制药-零售-医养"大健康生态圈的最后一块拼图 。本次全球发售1.08亿股,其中香港公开发售约10%,国际发售约90%。基石投资者已锁定占发行规模逾46%,基石占比接近最高限额。机构真金白银入场:基石比例高,机构参与热度足数据是最诚实的信号。据招股书披露,基石投资者航空港科技资本(香港)及Aurora SF将按发售价认购总金额约3.89亿港元的股份,占全球发售规模逾46%,这一比例在近期港股IPO中处于较高水平。基石锁定比例高意味着上市后可流通筹码有限,对二级市场价格支撑更强。此外,基石锁定期超过传统规定的6个月,进一步增强了市场的预期。获客成本极低:仅为同行业的六十分之一在医疗服务行业,获客成本是决定盈利天花板的关键变量。同仁堂医养背靠始创于1669年的"同仁堂"金字招牌,品牌壁垒的经济价值可以用一个数字概括:2024年推广费占收入比例仅约0.2%。然而就诊人次却从2022年的132.1万飙升至2024年的297.7万,CAGR高达50.1%。2025年前9月达253.6万,同比再增21.5%。会员从43.6万增至76.7万(2025年9月),复购粘性强劲。随着收入规模扩大,同行需要花在营销上的每一分钱,对同仁堂医养而言几乎都可以直接转化为利润。这是任何竞争对手都无法在短期内复制的护城河。盈利拐点已确立:经调整净利润增长29%对于处于上市窗口的成长型企业,投资者最关心的是:盈利趋势是向上还是向下?答案很明确——向上,且加速。财务数据显示,公司已展现出稳健的盈利能力。2022年至2024年,公司已由亏损923万元转为盈利4620万元,经调整净利润达6173万元,增长达到29%;毛利同期从1.43亿元增至2.22亿元,年复合增长率为 24.8%;2024年现金转化率87.2%,有息债务占比仅11.56%,持有现金2.25亿元,盈利质量显著提升 。同仁堂医养当前的发展阶段与固生堂上市时高度相似,盈利能力刚进入释放通道,增长最快的阶段可能尚未到来。复制增长阶段:计划新增20家医疗机构中医医疗服务是业绩基本盘,公司已构建包含25家医疗机构的分级诊疗网络,其中自有医疗机构12家,管理医疗机构12家,此外还有1家互联网医院提供线上诊疗服务。截至2024年就诊人数约300万人,CAGR高达50.12%;2025年前9月约253.6万,同比再增21.5%;会员数量约74万人,合作药店约500余家。作为同仁堂集团打开增长空间的核心业务,医疗服务板块规模还需要更强力的支持与扩张。根据其募集资金使用披露,该公司计划新收购5家医疗机构、以轻资产的方式新建5家医疗机构,并额外向5-10家医疗机构提供管理服务。可见,其未来快速扩张的战略清晰,"收购+轻资产新建+管理输出"三路径协同。非"名医驱动": 依靠标准化"体系驱动"对中医医疗服务企业而言,最大的成长瓶颈在于"名医能否复制"。同仁堂医养正在用一套体系化的方法论回答这个问题。公司向上游延伸,自建了供应链体系,完成了端到端的产业链闭环。除药品外,健康产品销售也实现了品牌价值的商业化变现。公司已获授权在浙江省独家销售同仁堂爆款安宫牛黄丸系列产品,截至最后实际可行日期,公司已向超过4000家机构客户销售健康产品及其他产品。此外,公司将云数字化系统扎根进网络内每一家医疗机构,通过实时数据分析及管理,用智能系统代替"院长",正在向"人机协作式"新型连锁医疗管理方式过渡。让增长不再完全依赖于个别名医的"人治",而是依托可复制的运营体系、数字化中台和人才培养机制,实现规模化、标准化扩张。AI+中医:医药数据壁垒深厚作为同仁堂集团在中医服务领域唯一战略性布局的载体,同仁堂医养正站在传统中医与人工智能交汇的历史拐点上 。同仁堂集团近期积极推动AI技术在中医药领域的落地应用,已与小米联合打造"AI智能中医药健康服务智能体",将传统中医智慧与现代AI技术深度融合,形成"咨询—建议—服务—购药"的服务闭环 。展望未来,万亿规模的中医医疗服务市场正迎来龙头整合的黄金窗口期。同仁堂医养以多轮驱动的发展模式、稳健的财务基础及AI技术的前瞻布局,不仅完成了老字号资本版图的最后一块"拼图",更开启了中医服务与前沿科技深度融合的新纪元。随着上市募集资金的到位,相信同仁堂医养有望加速推进核心业务的全面AI转型,在万亿级中医医疗服务市场中持续巩固龙头地位,引领行业迈向智能化新时代。转载自格隆汇 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Dida Inc. (02559.HK) Announced 2025 Annual Results, RMB 138 Million Adjusted Net Profit ACN Newswire

Dida Inc. (02559.HK) Announced 2025 Annual Results, RMB 138 Million Adjusted Net Profit

HONG KONG, March 24, 2026 - (ACN Newswire via SeaPRwire.com) – Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK), a leading technology-driven mobility platform, announced the audited consolidated annual results for the year ended December 31, 2025.Financial Highlights:- Revenue was RMB502.4 million for the year ended December 31, 2025, compared to RMB787.2 million for the year ended December 31, 2024.- Gross profit was RMB332.9 million for the year ended December 31, 2025, compared to RMB567.0 million for year ended December 31, 2024.- Net profit was RMB129.8 million for the year ended December 31, 2025, compared to RMB1,004.3 million for the year ended December 31, 2024.- Adjusted net profit (non-IFRS measure) was RMB137.9 million for the year ended December 31, 2025, compared to RMB221.4 million for the year ended December 31, 2025.Operation Highlights:- Gross transaction value amounted to RMB4.7 billion and the total number of orders reached 80.9 million for the year ended December 31, 2025.- Registered users reached over 415 million as of December 31, 2025.- The number of certified private car owners reached approximately 21 million as of December 31, 2025.Business OutlookMobility-related business 2025 marked a pivotal year as the Company transitioned from a single-focus carpooling platform toward a more integrated mobility and vehicle services platform. In 2025, the Company launched ride-hailing aggregation platform services to diversify service offerings. Such services are intended to complement the carpooling business by addressing additional mobility scenarios, including short-to-medium distance and immediate travel needs, in addition to the medium-to-long distance and pre-arranged travel scenarios typically served by carpooling. The Company also commenced used car trading referral services to expand business scope along the vehicle ownership lifecycle and enhance engagement within the Company’s car owner ecosystem. The Company believes carpooling in China is still at its early stage of development, with significant market demand yet to be fully released and the benefits of carpooling not fully recognized by the public. The Company will remain committed to innovation as the Company continues to develop unique competitive strengths and value around mobility scenarios to better serve the user base. In the future, the Company plans to further develop ride-hailing aggregation platform services and other mobility-related services and to continue to expand service offerings.For the full announcement of Dida for the annual results ended December 31, 2025, please visit:https://manager.wisdomir.com/files/594/2026/0320/20260320220001_60101381_en.pdf About Dida Inc.Dida Inc. (“Dida” or the “Company”, Stock Code: 02559.HK) is a leading technology-driven mobility platform in China. The Company creates more transit capacity with less environmental impact by providing carpooling marketplace services to pair up riders with private car owners if they are heading in similar directions at compatible times. It also provides ride-hailing aggregation platform services to address additional mobility scenarios. Dida makes the mobility ecosystem greener and more efficient, and each trip experience warm and enjoyable.Forward-Looking StatementsThis press release contains forward-looking statements relating to the business outlook, forecast business plans and growth strategies of the Company. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond the control. These forward-looking statements may prove to be incorrect and may not be realized in future. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding these risks and uncertainties is included in the other public disclosure documents on the corporate website. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
嘀嗒出行(02559.HK)公布2025年全年业绩 经调整净利润达1.38亿元人民币 ACN Newswire

嘀嗒出行(02559.HK)公布2025年全年业绩 经调整净利润达1.38亿元人民币

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 中国领先的技术驱动移动出行平台嘀嗒出行(“嘀嗒”或“公司”,股票代码:02559.HK)公布了截至2025年12月31日止年度的经审计综合年度业绩。财务亮点:-截至2025年12月31日止年度,收入为人民币5.02亿元,2024年同期为7.87亿元。-截至2025年12月31日止年度,毛利为人民币3.33亿元,2024年同期为5.67亿元。-截至2025年12月31日止年度,净利润为人民币1.30亿元,2024年同期为10.04亿元。-截至2025年12月31日止年度,经调整净利润(非国际财务报告准则计量)为人民币1.38亿元,而2024年同期为2.21亿元。运营亮点:-截至2025年12月31日止年度,交易总额达人民币47亿元,订单总数达到8090万。-截至2025年12月31日,注册用户数超过4.15亿。-截至2025年12月31日,认证私家车主数量达到约2100万。业务展望:出行相关业务2025年是嘀嗒出行从专注于顺风车的平台,向更为综合的出行及车辆服务平台转型的关键之年。2025年,嘀嗒出行推出了聚合打车业务,来进一步丰富平台的出行场景,使“中短途+立即出发“的即时出行需求与顺风车”中长途+预约出行“的场景形成有效互补,增强用户在不同出行决策场景下的选择弹性。嘀嗒出行还开启了二手车交易线索业务,拓展车辆全生命周期的业务范围,并提升车主生态的用户参与度。嘀嗒出行认为,顺风车在中国仍处于早期发展阶段,有潜在的巨大市场需求还未被充分释放,而顺风车的益处还未被完全认知。嘀嗒出行将持续致力于创新,围绕平台的出行场景,继续发展平台独特的竞争优势和价值,以更好地服务用户群体。未来,嘀嗒出行计划进一步发展聚合打车业务及其他出行相关服务,并持续扩展服务品类。有关嘀嗒出行截至2025年12月31日止年度全年业绩公告的完整内容,请访问:https://manager.wisdomir.com/files/594/2026/0320/20260320220001_60101381_en.pdf关于嘀嗒出行嘀嗒出行("嘀嗒"或"公司",股票代码:02559.HK)是中国领先的技术驱动型出行平台。公司通过提供顺风车平台服务,为乘客和出行路线及时间相近的私家车主进行匹配,从而在不增加环境负担的前提下创造了更多运力。公司还提供聚合打车服务,以满足更多元的出行场景需求。嘀嗒出行致力于让出行生态更绿色、更高效,让每一次出行体验温暖而愉悦。前瞻性声明本新闻稿包含有关公司业务前景、预测业务计划和增长战略的前瞻性陈述。这些前瞻性陈述基于公司目前信息,并基于本新闻稿发布时的前景进行陈述。它们基于某些期望、假设和前提,其中一些是主观的或不可控的,可能被证明是不正确的,未来可能无法实现。前瞻性陈述背后存在大量风险和不确定性。有关这些风险和不确定性的更多信息,请参阅公司网站上的其他公开披露文件。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
UK Gambling Levy Rollout Raises Sector Concerns iGame

UK Gambling Levy Rollout Raises Sector Concerns

(AsiaGameHub) - The introduction of a new statutory levy intended to finance gambling harm services throughout the UK has generated apprehension among charities and support organizations, as the initial funding allocations leave many facing an uncertain future. UK Gambling Harm Fund Faces Backlash Over Transition Timing This system, projected to generate between GBP 90 million ($120.8 million) and GBP 100 million ($134.2 million), is designed to offer sustained support for harm prevention, addiction treatment, and research. The government directs the distribution of these funds, with prevention services in England being overseen by the Office for Health Improvement and Disparities (OHID). However, the recent disclosure of initial funding outcomes has brought tensions within the sector to the forefront. Organizations that applied for transitional support were notified of decisions less than two weeks before the commencement of the new funding period, leaving insufficient time for planning. The Gambling Lived Experience Network (GLEN), which represents individuals and groups impacted by gambling harm, cautioned that the short notice period jeopardizes the stability of crucial services. The group suggested that rather than ensuring continuity, the process might lead to some organizations losing funding without a clear understanding of the consequences for those they assist. GLEN stated that the current situation has compelled some providers to make difficult decisions regarding whether to continue operations or cease entirely. The organization indicated that without the maintenance of current service levels, the transition could create voids in support for vulnerable individuals who depend on specialized assistance. UK Gambling Levy Structure Faces Questions Over Clarity The design of the levy has also faced scrutiny. Funding is divided among research, prevention, and treatment, with half allocated to treatment services. NHS England, which is currently undergoing substantial internal reorganization, is responsible for these services. Stakeholders have highlighted a lack of clarity and communication regarding the handling of treatment-related decisions. While GLEN acknowledged that OHID has made efforts to engage with the sector despite having limited prior experience with gambling harms, it expressed frustration over what it perceives as inadequate overall consultation. The group contrasted this with what it described as minimal engagement from other government bodies involved in the transition. Another significant concern revolves around whether the new framework accurately reflects real-world needs. Critics contend that funding decisions appear to have been made without a comprehensive evaluation of existing services and demand, increasing the likelihood that effective programs could be discontinued. The move to a government-controlled model also signifies a gradual transition away from established charity-led structures, including the work previously coordinated by organizations like GambleAware. Voices from within the sector have emphasized the importance of maintaining stability during this transition to prevent disruptions in care. Despite the criticisms, there are indications of cautious optimism. Officials have outlined plans to adopt a "test and learn" methodology, aiming to refine the system over time and enhance evidence-based decision-making. This article is provided by a third-party. AsiaGameHub (https://asiagamehub.com/) makes no warranties regarding its content. AsiaGameHub delivers targeted distribution for iGaming, Casino, and eSports, connecting 3,000+ premium Asian media outlets and 80,000+ specialized influencers across ASEAN.
More
Fujitsu and Umios conduct joint pilot project for electronic traceability system to visualize seafood distribution JCN Newswire

Fujitsu and Umios conduct joint pilot project for electronic traceability system to visualize seafood distribution

Kawasaki and Tokyo, Japan, Mar 24, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited and Umios Corporation today announced the successful completion of a joint pilot project for an electronic traceability system to trace and visualize seafood distribution information. This initiative, conducted on February 1, 2026, aims to support the countering of illegal, unreported and unregulated (IUU) fishing, which is increasingly important for securing sustainable marine resources. The experiment focused on bluefin tuna farmed by the Umios Group in Wakayama Prefecture, establishing a mechanism for consumers to check distribution information from the farm to retail stores via smartphone. The project successfully validated the system's effectiveness for wider implementation in society. Both companies aim to commence operation of this system by fiscal year 2027 for some fish species handled by the Umios Group. In recent years, while demand for seafood has increased globally due to population growth and rising health consciousness, natural marine resources are declining, and securing sustainable marine resources has become an urgent issue. Countermeasures against IUU fishing are particularly critical, and countries worldwide are tightening marine resource management and fishing regulations. A common challenge for the fisheries industry is establishing mechanisms to clearly demonstrate and prove non-involvement with IUU fishing throughout the entire process, from procurement to distribution.The Umios Group has positioned "Action for preserving biodiversity and ecosystem" as one of its material issues in the sustainability strategy of its medium-term management plan, "For the ocean, for life 2027," and is promoting the establishment of an electronic traceability system that can quickly and reliably prove that the seafood it handles is unrelated to IUU fishing.Overview of the Pilot ProjectDate: February 1, 2026 (Saturday)Locations: Umios Marine Corporation Kushimoto Office (Wakayama Prefecture, aquaculture farm), Okuwa Co., Ltd. Izumi-Oda Store (Osaka Prefecture, retail store)Target Seafood: Bluefin tuna farmed at Umios Marine Corporation Kushimoto OfficeDetails: A pilot project for an electronic traceability system enabling consumers who purchased the target bluefin tuna at Okuwa Co., Ltd. Izumi-Oda Store to check the production history (from farming and landing to processing and sales) using smartphones, along with a consumer awareness survey.System Used: A system developed as a prototype by Fujitsu, which records and visualizes the entire production history. It was designed utilizing a traceability solution from Fujitsu Sustainability Value Accelerator[1] offered through Fujitsu's business model Uvance, which addresses societal challenges.Results: The experiment demonstrated that the system can reliably record and visualize production history information for the target bluefin tuna. Furthermore, in the consumer awareness survey (35 valid responses), approximately 91% responded that they "would consider or refer to it when purchasing," approximately 77% said it "leads to a sense of security and trust," and approximately 77% also stated that they "would be willing to pay an additional price for products with traceability information." This indicates that electronic traceability can also function as added value for products.Moving forward, both companies will leverage the insights gained from this pilot to expand the target fish species, enhance the system, and extend its application across the entire supply chain. This will accelerate the social implementation of transparency in seafood distribution and IUU fishing countermeasures.Fujitsu will drive progress toward both enhancing corporate value based on trust and ensuring the sustainability of natural resources by realizing cross-company and cross-industry value chain traceability through Uvance.(1) Fujitsu Sustainability Value Accelerator: A suite of services from Fujitsu that collects verifiable traceability data across companies and industries, enhances value chain transparency, and supports overall optimization and the creation of new business models.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuAbout Umios CorporationUmios Corporation is one of the largest fishing and food companies in the world, with a history dating back to its founding in Japan in 1880. Guided by its purpose "For the ocean, for life," Umios is committed to contributing to the happiness and well-being of all through authentic, safe, and healthy food. Find out more: https://www.umios.com/en/Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
TINGYI (CAYMAN ISLANDS) HOLDING CORP. Business Momentum Sustained in 2025, United for a New Journey, with GPM Rising to 34.8%, Profit Attributable to Shareholders Up 20.5% YoY ACN Newswire

TINGYI (CAYMAN ISLANDS) HOLDING CORP. Business Momentum Sustained in 2025, United for a New Journey, with GPM Rising to 34.8%, Profit Attributable to Shareholders Up 20.5% YoY

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - On March 23, 2026, Tingyi (Cayman Islands) Holding Corp. (0322.HK, the “Company”, together with its subsidiaries, the “Group”) is pleased to announce its 2025 annual results. In 2025, amid drastic changes in consumer behaviours and a complex market environment, the Group remained firmly committed to the consumer-centric approach, advanced the high-quality development in a coordinated manner, promoted product innovation and upgrades to precisely meet the demands of diverse scenario-based needs, while accelerating the expansion into high-growth channels. It comprehensively improved overall operational efficiency and drove steady growth of all key financial indicators. For the twelve months ended on December 31, the Group’s revenue decreased by 2.0% year-on-year to RMB 79.068 billion. Among which, the revenue from the Instant Noodles Business was RMB28.421 billion, while the revenue from the Beverages Business was RMB50.123 billion. The gross profit margin grew 1.7 percentage points to 34.8% year-on-year, EBITDA increased by 10.2% year-on-year to RMB 10.607 billion. The profit attributable to shareholders of the Company increased significantly by 20.5% year-on-year to RMB4.501 billion. The directors recommended the payment of a final dividend and a special final dividend of RMB39.92 cents and RMB39.92 cents per ordinary share respectively. Dividend payout ratio for the year remained at 100%.Financial Summary For the twelve months ended 31 December RMB’00020252024ChangeRevenue79,068,02280,650,914↓ 2.0%Gross margin34.8%33.1%↑ 1.7ppt.Gross profit of the Group27,531,70426,695,643↑ 3.1%EBITDA10,606,5229,627,802↑ 10.2%Profit for the period5,175,8524,322,135↑ 19.8%Profit attributable to owners of the Company4,500,6983,734,429↑ 20.5%Earnings per share (RMB cents) Basic79.8666.28↑ 13.58 centsDiluted79.8466.28↑ 13.56 centsAs at 31 December 2025, cash at bank and on hand (including long-term time deposits) was RMB19,486.056 million, representing an increase of RMB3,483.388 million when compared to 31 December 2024. Gearing ratio was -29.8%.In 2025, China's economy demonstrated resilience with a 5% year-on-year GDP growth. However, the food and beverage market entered into the stage of stock competition and demand upgrading for functional and emotional values. Brand, quality, and flavors remained key drivers of purchasing decisions. Additionally, emerging formats such as instant retail, snack discount stores, and membership stores had brought about drastic changes in channels and consumer behaviors. Against the backdrop of intensifying market competition and evolving consumption patterns, a company's core competitiveness increasingly lies in building a strong moat for their core brands. Those that continuously drive product innovation and channel optimization around consumer needs will be more agile in capturing market opportunities, strengthening consumer trust, and ultimately achieving high-quality and sustainable long-term development.In 2025, the gross profit of the Instant Noodles business improved steadily. The Group’s revenue from the Instant Noodles Business was RMB28.421 billion, which grew slightly year-on-year, accounting for 35.9% of the Group’s total revenue. During the year, due to favorable raw material prices and selling prices, the gross profit margin of instant noodles expanded by 1.1 percentage points year-on-year to 29.7%, and the profit attributable to shareholders of the Company for the year of 2025 in the Instant Noodles Business increased significantly by 10.1% year-on-year to RMB 2.252 billion, driven by the year-on-year increase in gross profit margin. During the year, in the face of intensifying industry competition, the Instant Noodles Business steadily advanced its core strategy of “consolidating blockbuster products, seizing the popular flavors track, and cultivating innovative products.” By continuously improving the product portfolio and forging deep collaborations with popular IPs, it effectively amplified brand presence and steadily optimized gross margin structure. On the product front, the business relied on deep cultivation of core blockbuster products and iterative flavor upgrades, while closely aligning with evolving consumer trends to precisely target the health-focused and premium market segments, tapping into new growth opportunities. On the marketing front, it leveraged mainstream social platforms such as Bilibili and Xiaohongshu to conduct omnichannel communication, combined with cross-industry collaborations with well-known IPs to reinforce the brand perception of high-end and convenient consumption. As a result, brand influence and market recognition improved significantly. Meanwhile, guided by aerospace-grade quality standards, the business promoted the full application of aerospace patented temperature control technology in the production line, fully demonstrating the brand’s differentiated advantages in product quality and technological innovation.The Beverages Business firmly executed the strategy of “consolidating core products and developing innovative products”, the revenue from the Beverages Business was RMB50.123 billion, accounting for 63.4% of the Group’s total revenue. During the year, due to favorable raw material prices and optimized product mix, the gross profit margin of Beverages expanded by 2.2 percentage points year on-year to 37.5%. Driven by a year-on-year expansion of gross profit margin, the profit attributable to shareholders of the Company in the Beverages Business for the year of 2025 increased significantly by 18.5% year-on-year to RMB 2.274 billion. During the year, the Beverages Business strengthened its core category advantages and proactively positioned itself in emerging tracks, establishing a collaborative growth model across the full product portfolio. On the product front, while consolidating core products, it continuously expanded into incremental growth segments by launching high-quality sugar-free offerings and aligning with the wellness consumption trend to create herbal wellness scenarios, successfully opening up new growth spaces such as products made from homologous medicinal and food materials. On the marketing front, the Company deepened IP collaborations to broaden audience reach, enhanced its presence in cultural tourism channels and high-end hotel partnerships, and targeted premium consumption scenarios. These efforts consistently elevated brand value, providing strong support for the business to achieve steady operations and sustainable growth.Mr. Wei Hong-Chen, Chief Executive Officer, commented, “As the first year of the 15th Five-Year Plan period, 2026 is expected to see expanding domestic demand become a key driver of economic growth under a more proactive and effective macroeconomic policy, while the consumer market will also usher in a critical window of profound transformation. The food and beverage industry will closely follow the theme of high-quality development, and consumption stratification will become more refined. Functional attributes, emotional resonance, and green concepts are shifting from trends to mainstream factors, becoming core elements driving brand growth. In the face of opportunities and challenges in the new cycle, the Group will be guided by the spirit of “Back to Day 1” as its strategic direction, embracing the efficiency, agility and entrepreneurial drive of our founding days, and building a platform that encourages honesty, bold experimentation and mutual growth, thus fully unleashing the vitality of all employees. While unleashing organizational vitality, we will continue to strengthen our foundational R&D capabilities and digital operation systems. Rooted in the health needs of the nation, we will drive product iteration and upgrades through technological innovation, continuously elevate product value, and align high-quality supply with the evolving consumption landscape. Adhering to the “economic-ESG” sustainable development philosophy, we will internalize social responsibility as the foundation of our development, solidify user trust through quality products, build a brand moat with long-term value, and create a sustainable and stable return system for shareholders, propelling the Group toward steady and sustained progress in the new stage of high-quality development.”About Tingyi (Cayman Islands) Holding Corp. (0322.HK)Tingyi (Cayman Islands) Holding Corp. (the “Company”), and its subsidiaries (the “Group”) specialise in the production and distribution of instant noodles and beverages in the People’s Republic of China (the “PRC”). The Group started its instant noodle business in 1992, and expanded into instant food business and beverage business in 1996. In March 2012, the Group further expanded its beverage business by forming a strategic alliance with PepsiCo for the beverage business in the PRC. The Company exclusively manufactures, bottles, packages, distributes and sells PepsiCo soft drinks in the PRC. After years of hard work and accumulation, “Master Kong” has become one of the best-known brands among consumers in the PRC.For enquiries, please contact:Investor EnquiriesInvestor Relations Team, Tingyi (Cayman Islands) Holding Corp.E-mail: ir@tingyi.comChristensen China LimitedStephanie ChenE-mail: stephanie.chen@christensencomms.comTel: +852 2117 0861 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
康师傅控股有限公司2025年业务持续向好 凝心聚力再启新程 ACN Newswire

康师傅控股有限公司2025年业务持续向好 凝心聚力再启新程

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 2026年3月23日,康师傅控股有限公司(0322.HK,以下简称"公司",连同其附属公司"集团")发布2025年年度业绩公告。2025年,在消费行为剧烈变革与市场环境复杂多变的背景下,本集团始终坚持以消费者为中心,统筹推进高质量发展,推动产品创新升级,精准满足多元场景需求,同时加速开拓高增长渠道,全面提升整体运营效能,推动各项财务指标稳健发展。截至2025年12月31日止十二个月,集团收益同比衰退2.0%至790.68亿人民币。其中,方便面事业收益284.21亿人民币,饮品事业收益为501.23亿人民币。毛利率同比提高1.7个百分点至34.8%,EBITDA同比增长10.2%至106.07亿人民币,本公司股东应占溢利同比成长20.5%至45.01亿人民币。董事会建议派发末期股息每股普通股人民币39.92分及特别末期股息每股普通股人民币39.92分,全年派息率达100%。财务摘要 截至12月31日止12个月 人民币千元2025年2024年变动收益79,068,02280,650,914↓ 2.0%毛利率(%)34.8%33.1%↑ 1.7个百分点集团毛利27,531,70426,695,643↑ 3.1%扣除利息、税项、折旧及摊销前盈利(EBITDA)10,606,5229,627,802↑ 10.2%本期溢利5,175,8524,322,135↑ 19.8%本公司股东应占溢利4,500,6983,734,429↑ 20.5%每股溢利(人民币分) 基本79.8666.28↑ 13.58分摊薄79.8466.28↑ 13.56分于2025年12月31日之银行存款及现金(含长期定期存款)为人民币19,486,056千元,相较2024年12月31日增加人民币3,483,388千元,净负债与资本比率为-29.8%。2025年,中国经济在GDP同比5%的增长中展现韧性。但食品饮料市场进入存量博弈,以及对功能价值与情绪价值需求升级阶段。品牌、品质与风味仍是购买决策的重要驱动因素。此外,即时零售、零食折扣店、会员店等新兴业态带来渠道与消费行为剧烈变革。在市场竞争日趋激烈、消费行为持续演变的背景下,企业的核心竞争力愈发体现在核心品牌的护城河建设。能够围绕消费者需求,持续推动产品创新与渠道优化的企业,将更敏捷地捕捉市场机遇,巩固消费者信任,进而实现高质量、可持续的长远发展。2025年,方便面事业的毛利结构持续改善。方便面事业收益为284.21亿人民币,同比微幅增长,占集团总收益35.9%。年内,因原材料价格及售价有利,使方便面毛利率同比提高1.1个百分点至29.7%,由于毛利率同比提高带动,令方便面事业2025年全年的本公司股东应占溢利同比大幅增长10.1%至22.52亿人民币。年内,面对日趋激烈的行业竞争,方便面业务扎实推进"巩固大单品、占领大口味赛道、培育创新产品"的核心战略,通过持续完善产品矩阵,与热门IP深度联动,有效放大品牌声量,稳步优化毛利结构。产品端,依托核心大单品深耕与口味迭代升级,同时紧密贴合消费趋势变化,精准布局健康化、高端化赛道,精准切入新增量市场。营销端,依托B站、小红书等主流社交平台开展全域传播,叠加知名IP跨界合作,深化高端便捷的品牌认知,品牌影响力与市场认知度显著提升。同时,以航天品质为引领,推动航天专利温控技术在生产线全面落地应用,充分彰显品牌在产品品质与科技含量的差异化优势。饮品事业坚定实施"巩固核心单品、发展创新产品"战略。饮品事业整体收益为501.23亿人民币,占集团总收益63.4%。年内,因原材料价格有利及产品组合优化,使饮品毛利率同比提高2.2个百分点至37.5%。由于毛利率同比提高带动,令饮品事业2025年全年本公司股东应占溢利同比大幅提高18.5%至22.74亿人民币。年内,饮品事业通过深化核心品类优势与前瞻性布局新兴赛道,构建全品类协同增长格局。产品端,在稳固核心单品的基础上,持续拓展增量赛道,推出高品质无糖产品,并紧扣养生消费趋势,打造草本养生场景,成功开辟药食同源等新增量空间。营销端则持续强化IP深度合作拓宽受众圈层,同时强化文旅渠道布局及高端酒店合作,锚定高端消费场景,持续提升品牌价值,为业务实现稳健经营与可持续增长提供有力支撑。康师傅首席执行官魏宏丞先生表示:"2026年作为"十五五"开局之年,预计在更加积极有为的宏观政策下,扩大内需将成为经济增长的关键着力点,消费市场也将随之迎来深度变革的关键窗口。食品饮料行业围绕高质量发展主线持续演进,消费分层愈加精细,功能价值、情绪共鸣与绿色理念正从趋势走向主流,成为驱动品牌增长的核心要素。面对新周期中的机遇与挑战,集团将以"Back to Day 1"的精神为战略引领,回归创业初期的高效敏捷与狼性拼搏文化,打造敢讲真话、勇于尝试、共同成长的平台,充分激发全员活力。在释放组织活力的同时,我们将持续夯实基础研发能力与数字化运营体系,立足国民健康诉求,以科技创新驱动产品迭代升级,推动产品价值不断跃迁,以高品质供给适配新消费结构。秉持"economic-ESG"可持续发展理念,我们将社会责任内化为发展底色,通过优质产品夯实用户信赖,以长期价值构建品牌护城河,为股东打造可持续的稳健回报体系,推动集团在高质量发展新阶段行稳致远。"关于康师傅控股有限公司(0322.HK)康师傅控股有限公司("本公司")及其附属公司("本集团")主要在中国从事生产和销售方便面及饮品。本集团于1992年开始生产方便面,并自1996年起扩大事业至方便食品及饮品;2012年3月,本集团进一步拓展饮料事业范围,完成与PepsiCo中国饮料事业之战略联盟,开始独家负责制造、灌装、包装、销售及分销PepsiCo于中国的非酒精饮料。"康师傅"作为中国家喻户晓的品牌,经过多年的耕耘与积累,深受中国消费者喜爱和支持。如有垂询,请联络:投资者查询康师傅控股有限公司投资者关系团队电邮:ir@tingyi.com汇思讯中国有限公司陈敏芝电邮:stephanie.chen@christensencomms.com电话:+852 2117 0861 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
全景业务布局+AI双轮驱动 麦迪卫康业绩扭亏为盈打开广阔成长空间 ACN Newswire

全景业务布局+AI双轮驱动 麦迪卫康业绩扭亏为盈打开广阔成长空间

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 3月23日,麦迪卫康正式发布2025年度业绩公告。 数据显示,公司年内溢利约人民币698万元,盈利能力显著修复,全年扭亏为盈,经营性现金流状况持续好转。 业绩改善主要得益于“AI+数字化”带动核心主营业务持续稳健增长,叠加公司聚焦高毛利优质项目,有效带动整体毛利水平显著提升。此次公司财务表现展现出强劲的修复弹性,是公司发展历程中的重要里程碑。 一方面,标志着公司聚焦主业、优化业务结构的战略取得实质性成效,经营质量与盈利能力迈入全新阶段,为后续稳健发展筑牢财务根基; 另一方面,充分印证公司核心业务具备强劲增长韧性与市场竞争力,高毛利项目布局持续释放效益,也为公司深化医疗健康服务布局、拓展优质业务版图注入更强信心,进一步巩固行业竞争力与可持续发展能力。3C服务体系覆盖全产业链 技术创新构筑核心竞争力经营效率的跨越式进步,离不开公司清晰的业务布局与精准的战略定位。 在业务布局方面,麦迪卫康以创新数字医疗服务提供商为定位,打造独具竞争力的「3C服务体系」,涵盖专业医学内容服务(Content)、高端学术会议服务(Conference)、企业市场推广服务(Corporation)三大核心领域,形成了覆盖医疗全产业链的服务闭环,为业务高质量发展筑牢根基。2025年,公司数字化医学平台的运营步入高质量发展的新阶段。 该平台不仅实现了专业医疗群体的高密度覆盖,更在海量的学术交流与卫教传播中,构筑起一套精准、专业且具备高度粘性的知识服务体系。 这种深度的数字化转型,不仅显著提升了医学内容的传播效能与学术影响力,更在赋能医生临床决策、助力健康知识普及方面发挥了关键作用,转化为推动行业进步的实质性力量,进一步巩固了公司在数字医疗生态中的引领地位。持续的技术创新,是驱动麦迪卫康高质量增长的核心引擎。 在技术研发领域,公司拥有多项软件著作权与发明专利,自主研发的长颈鹿系列数智平台已吸引数十万名医生入驻,显著提升医疗服务与运营管理效率。 2024年,公司持续深化AIGC场景落地,创新推出「AI智能体+医生众创」模式,助力医生回归高价值诊疗与科研工作; 同时依托区块链技术成功获得数据服务商资质,实现医学内容确权与授权运营,为医疗数字化生态建设树立行业标杆。2025年,公司深入推进AI智能体的研发与场景应用探索,致力于与医疗专业人士协同,打造「AI+人工」深度融合的医学内容数据标注及版权内容生产体系,并与数字资产交易平台业务形成有机衔接。 此外,依托专病管理AI智能体所取得的阶段性突破,公司正进一步将数智化能力向产业上下游延伸,前瞻性地探索智能专病机器人赛道; 同时,通过对柏慧康生物的战略投资,公司正积极探索在多组学创新检测领域的落地应用并已取得阶段性进展,借此构建起立体化的医疗创新服务网络。全国服务网络纵深覆盖 打开长期价值成长空间依托成熟的业务体系与核心技术支撑,麦迪卫康已搭建起覆盖全国的专业服务网络。 目前,公司在全国设立近10家经营机构,重点布局北京、上海、南京等核心医疗枢纽城市,服务合作三级医疗机构超3000家,其中包括北京天坛医院、阜外医院等国内顶尖三甲医院。同时,公司深度参与卒中中心、胸痛中心等重点专科建设,构建起纵向贯通、横向协同的全域专科医疗服务体系,为业务高效落地与市场持续拓展提供了坚实保障。广泛覆盖的服务网络与专业高效的服务能力,让麦迪卫康积累起优质且多元的客户群体,行业龙头地位持续巩固。 在数字医疗领域,公司自有互联网医疗平台已汇聚注册医生超5万名、注册患者近36万人次,2025年线上咨询量突破50万次,同比增长超19%,实现优质医疗资源高效触达,有效缓解医疗资源分配不均难题。从行业发展趋势来看,在人口老龄化加剧、慢性病管理需求攀升、政策持续赋能及AI数字技术深度渗透等多重驱动下,中国数字医疗产业正迎来黄金发展期,据中商产业研究院数据预测,2025年中国数字医疗市场规模预计达5800亿元, 2031年突破1.2万亿元,广阔的市场增量为麦迪卫康这类具备核心技术壁垒与全链条布局的领军企业,提供了持续成长与价值释放空间。麦迪卫康以「3C服务体系」为基座,以技术创新与服务升级为引擎,凭借覆盖全国的服务网络、广泛优质的客户资源以及前瞻性的战略布局,在行业内构建了独特的竞争优势与地位。 未来,随着数字医疗产业的持续升温与公司业务的不断深化,公司将紧抓医疗智能化转型的时代机遇,聚焦AI小模型赋能,全面拓展业务版图,夯实「AI+区块链」技术底座,探索搭建全流程智能闭环体系。 同时以「医学专业服务+数字化技术」双轮驱动,持续拓宽业务边界、优化内部运营效能,在数字医疗赛道上实现更高质量的发展,打开广阔成长空间。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More